The National Institute for Clinical Excellence has ruled that taxanes Taxotere and Taxol can be used to treat advanced breast cancer where other drugs have not worked or are unsuitable. The Association of the British Pharmaceutical Industry welcomed the decision , but said it should have been reached without the need for an appeal against NICE's original proposals. It also called for adequate funding.